FRA:NOT - Deutsche Boerse Ag - CH0012005267 - Common Stock - Currency: EUR
FRA:NOT (5/13/2025, 7:00:00 PM)
95.15
-4.2 (-4.23%)
The current stock price of NOT.DE is 95.15 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 54.56 | 640.37B | ||
LLY.DE | ELI LILLY & CO | 54.11 | 635.06B | ||
ZEG.DE | ASTRAZENECA PLC | 18.27 | 376.69B | ||
1JNJ.MI | JOHNSON & JOHNSON | 15.42 | 335.84B | ||
JNJ.DE | JOHNSON & JOHNSON | 14.68 | 319.38B | ||
NOV.DE | NOVO NORDISK A/S-B | 19.34 | 264.39B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.44 | 234.84B | ||
1SAN.MI | SANOFI | 13.4 | 220.74B | ||
SNW.DE | SANOFI | 13.37 | 220.35B | ||
SAN.PA | SANOFI | 13.29 | 219.03B | ||
6MK.DE | MERCK & CO. INC. | 9.71 | 171.37B | ||
PFE.DE | PFIZER INC | 7.08 | 115.98B |
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
NOVARTIS AG-REG
Lichtstrasse 35
Basel BASEL-STADT CH
Employees: 76057
Phone: 41613241111
The current stock price of NOT.DE is 95.15 EUR. The price decreased by -4.23% in the last trading session.
The exchange symbol of NOVARTIS AG-REG is NOT and it is listed on the Deutsche Boerse Ag exchange.
NOT.DE stock is listed on the Deutsche Boerse Ag exchange.
32 analysts have analysed NOT.DE and the average price target is 111.96 EUR. This implies a price increase of 17.66% is expected in the next year compared to the current price of 95.15. Check the NOVARTIS AG-REG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NOVARTIS AG-REG (NOT.DE) has a market capitalization of 187.93B EUR. This makes NOT.DE a Large Cap stock.
NOVARTIS AG-REG (NOT.DE) currently has 76057 employees.
The Revenue of NOVARTIS AG-REG (NOT.DE) is expected to grow by 7.74% in the next year. Check the estimates tab for more information on the NOT.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NOVARTIS AG-REG (NOT.DE) has a dividend yield of 3.84%. The yearly dividend amount is currently 3.37. Check the full fundamental report for a detailed analysis of NOT.DE dividend history, reliability and sustainability.
NOVARTIS AG-REG (NOT.DE) will report earnings on 2025-07-17, before the market open.
The PE ratio for NOVARTIS AG-REG (NOT.DE) is 12.75. This is based on the reported non-GAAP earnings per share of 7.46 and the current share price of 95.15 EUR. Check the full fundamental report for a full analysis of the valuation metrics for NOT.DE.
ChartMill assigns a technical rating of 2 / 10 to NOT.DE.
ChartMill assigns a fundamental rating of 7 / 10 to NOT.DE. NOT.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months NOT.DE reported a non-GAAP Earnings per Share(EPS) of 7.46. The EPS increased by 18.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 24.15% | ||
ROA | 12.87% | ||
ROE | 33.51% | ||
Debt/Equity | 0.61 |
ChartMill assigns a Buy % Consensus number of 68% to NOT.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 11.31% and a revenue growth 7.74% for NOT.DE